» Articles » PMID: 7730443

A Monoclonal Antibody to Alpha 4 Integrin Suppresses and Reverses Active Experimental Allergic Encephalomyelitis

Overview
Journal J Neuroimmunol
Specialty Neurology
Date 1995 Apr 1
PMID 7730443
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

In experimental allergic encephalomyelitis (EAE), circulating leukocytes enter the central nervous system (CNS) producing inflammation, myelin damage and paralysis. Prevention of leukocyte infiltration by an antibody against alpha 4 integrin suppressed clinical and pathological features of EAE in the guinea pig. Rapid clearance of leukocytes from the CNS and reversal of clinical findings were observed when anti-alpha 4 treatment was administered during active disease. Clinical improvement was accompanied by a marked decrease in abnormal pathological findings, including demyelination. Therefore anti-alpha 4 is an effective treatment of EAE and may be similarly useful in the treatment of autoimmune diseases such as multiple sclerosis.

Citing Articles

Midline-1 regulates effector T cell motility in experimental autoimmune encephalomyelitis via mTOR/microtubule pathway.

Wei Y, Li W, Huang J, Braunstein Z, Liu X, Li X Theranostics. 2024; 14(3):1168-1180.

PMID: 38323310 PMC: 10845203. DOI: 10.7150/thno.87130.


Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery.

van Schaik P, Zuhorn I, Baron W Int J Mol Sci. 2022; 23(15).

PMID: 35955549 PMC: 9368816. DOI: 10.3390/ijms23158418.


Chemokine-Driven Migration of Pro-Inflammatory CD4 T Cells in CNS Autoimmune Disease.

Heng A, Han C, Abbott C, McColl S, Comerford I Front Immunol. 2022; 13:817473.

PMID: 35250997 PMC: 8889115. DOI: 10.3389/fimmu.2022.817473.


and effects of AVA4746, a novel competitive antagonist of the ligand binding of VLA-4, in B-cell acute lymphoblastic leukemia.

Ruan Y, Kim H, Ogana H, Gang E, Li S, Liu H Exp Ther Med. 2021; 23(1):47.

PMID: 34934426 PMC: 8652384. DOI: 10.3892/etm.2021.10969.


Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.

Wyatt N, Speight R, Stewart C, Kirby J, Lamb C BioDrugs. 2021; 35(5):473-503.

PMID: 34613592 DOI: 10.1007/s40259-021-00496-5.